7.78
price up icon0.65%   0.05
after-market After Hours: 7.96 0.18 +2.31%
loading
Nuvectis Pharma Inc stock is traded at $7.78, with a volume of 111.79K. It is up +0.65% in the last 24 hours and up +0.52% over the past month. Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.
See More
Previous Close:
$7.73
Open:
$7.76
24h Volume:
111.79K
Relative Volume:
0.74
Market Cap:
$162.55M
Revenue:
-
Net Income/Loss:
$-22.38M
P/E Ratio:
-5.5177
EPS:
-1.41
Net Cash Flow:
$-15.54M
1W Performance:
-0.26%
1M Performance:
+0.52%
6M Performance:
+18.78%
1Y Performance:
+17.52%
1-Day Range:
Value
$7.48
$7.87
1-Week Range:
Value
$7.48
$8.15
52-Week Range:
Value
$4.44
$11.80

Nuvectis Pharma Inc Stock (NVCT) Company Profile

Name
Name
Nuvectis Pharma Inc
Name
Phone
360-837-7232
Name
Address
1 BRIDGE PLAZA, SUITE 275, FORT LEE
Name
Employee
13
Name
Twitter
Name
Next Earnings Date
2024-08-07
Name
Latest SEC Filings
Name
NVCT's Discussions on Twitter

Compare NVCT with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
NVCT
Nuvectis Pharma Inc
7.78 161.51M 0 -22.38M -15.54M -1.41
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.65 122.48B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.10 60.96B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.81 42.77B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.99 36.21B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.47 31.91B 3.81B -644.79M -669.77M -6.24

Nuvectis Pharma Inc Stock (NVCT) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-02-25 Initiated Maxim Group Buy
Mar-17-25 Initiated Laidlaw Buy
Jul-13-22 Initiated Ladenburg Thalmann Buy

Nuvectis Pharma Inc Stock (NVCT) Latest News

pulisher
10:14 AM

Why Nuvectis Pharma Inc. stock is on top investor watchlistsSkyrocketing investment returns - jammulinksnews.com

10:14 AM
pulisher
06:19 AM

Nuvectis Pharma Inc. Stock Analysis and ForecastSuperior returns - Autocar Professional

06:19 AM
pulisher
05:06 AM

What drives Nuvectis Pharma Inc. stock priceRecord-breaking capital gains - Autocar Professional

05:06 AM
pulisher
Jul 24, 2025

What analysts say about Nuvectis Pharma Inc. stockUnstoppable profit momentum - PrintWeekIndia

Jul 24, 2025
pulisher
Jul 22, 2025

Is Nuvectis Pharma Inc. a good long term investmentTremendous wealth creation - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

(NVCT) On The My Stocks Page - news.stocktradersdaily.com

Jul 22, 2025
pulisher
Jul 21, 2025

Nuvectis Pharma, Inc. Reports First Quarter 2025 Financial Results and Business Highlights - sg.finance.yahoo.com

Jul 21, 2025
pulisher
Jul 15, 2025

How Nuvectis Pharma Inc. stock performs during market volatilityFree Growth Investment Group - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

What makes Nuvectis Pharma Inc. stock price move sharplyHigh Confidence Trade Setups - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Why Nuvectis Pharma Inc. stock attracts strong analyst attentionProfitable Yet Secure Picks - Newser

Jul 15, 2025
pulisher
Jul 12, 2025

When (NVCT) Moves Investors should Listen - news.stocktradersdaily.com

Jul 12, 2025
pulisher
Jul 08, 2025

Nuvectis reports positive drug interaction study for cancer drug NXP900 By Investing.com - Investing.com Nigeria

Jul 08, 2025
pulisher
Jul 08, 2025

Nuvectis Pharma, Inc. Announces Successful Completion of A Drug-Drug Interaction Study in Healthy Volunteers - MarketScreener

Jul 08, 2025
pulisher
Jul 08, 2025

Nuvectis Pharma Announces Successful Completion of a Drug-Drug Interaction Study in Healthy Volunteers Supporting NXP900's Potential as a Combination Partner with Leading Therapies - GlobeNewswire

Jul 08, 2025
pulisher
Jul 02, 2025

Nuvectis Pharma, Inc. (NASDAQ:NVCT) Shares Purchased by Oppenheimer & Co. Inc. - Defense World

Jul 02, 2025
pulisher
Jul 01, 2025

(NVCT) Technical Pivots with Risk Controls - news.stocktradersdaily.com

Jul 01, 2025
pulisher
Jun 30, 2025

Nuvectis Pharma, Inc.(NasdaqCM: NVCT) added to Russell 3000 Index - MarketScreener

Jun 30, 2025
pulisher
Jun 29, 2025

Nuvectis Pharma (NASDAQ:NVCT) Lowered to “Sell” Rating by Wall Street Zen - Defense World

Jun 29, 2025
pulisher
Jun 25, 2025

Is Nuvectis Pharma, Inc. technically bullish or bearish? - MarketsMojo

Jun 25, 2025
pulisher
Jun 21, 2025

(NVCT) Proactive Strategies - news.stocktradersdaily.com

Jun 21, 2025
pulisher
Jun 20, 2025

Silicon Valley - FinancialContent

Jun 20, 2025
pulisher
Jun 18, 2025

Nuvectis Pharma: Still Interesting, But Still Too Risky To Jump In - Seeking Alpha

Jun 18, 2025
pulisher
Jun 18, 2025

Insiders of Nuvectis Pharma, Inc. (NASDAQ:NVCT) must be disappointed as stock fell 10% after recent purchases - Yahoo Finance

Jun 18, 2025
pulisher
Jun 18, 2025

Insider Stock Buying Of Nuvectis Pharma Delivers Return On US$2.19m Investment - simplywall.st

Jun 18, 2025
pulisher
Jun 13, 2025

Nuvectis Pharma Approves Proposals at Annual Meeting - TipRanks

Jun 13, 2025

Nuvectis Pharma Inc Stock (NVCT) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Nuvectis Pharma Inc Stock (NVCT) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Mosseri Marlio Charles
10% Owner
Jun 18 '25
Buy
8.05
28,043
225,746
2,976,203
Mosseri Marlio Charles
10% Owner
Jun 17 '25
Buy
8.11
5,399
43,786
2,948,160
Mosseri Marlio Charles
10% Owner
May 12 '25
Buy
8.11
21,167
171,664
2,942,761
Mosseri Marlio Charles
10% Owner
May 06 '25
Buy
8.59
12,444
106,955
2,896,565
Mosseri Marlio Charles
10% Owner
May 07 '25
Buy
8.59
12,317
105,770
2,908,882
Mosseri Marlio Charles
10% Owner
May 08 '25
Buy
8.65
2,650
22,922
2,911,532
Mosseri Marlio Charles
10% Owner
Feb 07 '25
Buy
5.00
240,000
1,200,000
2,884,121
BENTSUR RON
Chairman & CEO
Dec 24 '24
Buy
4.65
4,500
20,925
3,270,924
Mosseri Marlio Charles
10% Owner
Dec 13 '24
Buy
4.70
17,000
79,900
2,612,000
Poradosu Enrique
Chief Science & Business Off
Nov 19 '24
Buy
4.99
2,000
9,980
1,506,319
$23.40
price down icon 0.97%
$36.67
price up icon 0.22%
$103.95
price up icon 0.42%
$28.67
price up icon 3.99%
$115.31
price up icon 0.65%
biotechnology ONC
$291.47
price down icon 1.68%
Cap:     |  Volume (24h):